Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12Neoplasms 7cyclopia sequence 6Polycystic Ovary Syndrome 4Fatigue 4Obesity 3Multiple Myeloma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Neoplasms, Plasma Cell 2Hematologic Diseases 2Head and Neck Neoplasms 2Depression 2Weight Loss 1Warts 1Vomiting 1Vitamin D Deficiency 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sleepiness 1Sezary Syndrome 1Prostatic Intraepithelial Neoplasia 1Primary Myelofibrosis 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Periampullary Carcinoma Nos 1

Interventions

ublituximab 1ravulizumab 1eculizumab 1Sugars 1Rituximab 1OM 89 1Mitoxantrone 1LFB-R603 1Interferon beta-1a 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelitis, Transverse × Sugars × Clear all
NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡